基于PET/CT的适应性放疗在局部晚期非小细胞肺癌中的多中心yDEGRO ARO 2017-01队列研究
这项回顾性观察性队列研究纳入21个大学中心2010年1月至2013年12月治疗的347例III期非小细胞肺癌患者,评估PET/CT放疗计划对预后的影响。PET/CT融合计划趋向于更好的肿瘤学结局但无显著关联(HR=0.8,95%CI 0.56-1.16),具有一致计划策略的中心表现优于无偏好计划方法的中心(0.62,95%CI 0.41-0.94)。
要点
- 适应性放疗并连续缩减照射体积对患者生存无显著不利影响(HR=1.21,95%CI 0.89-1.64)。
- 放疗计划中使用PET/CT融合趋向于更好的肿瘤学结局,但无显著关联(HR=0.8,95%CI 0.56-1.16)。
- 具有一致计划策略的中心生存优于无偏好计划方法的中心(0.62,95%CI 0.41-0.94)。
核心结论
- 一致的计划策略对总生存有积极影响。
- 基于PET/CT的适应性放疗计划显示出相似的生存前景,并有望降低治疗体积。
- 未来研究需分析毒性以评估上述推理。
研究设计与样本
- 由德国放射肿瘤学会(DEGRO)青年DEGRO试验组开展的回顾性观察性队列研究(ARO 2017-01/NCT03055715)。
- 纳入21个大学中心2010年1月至2013年12月治疗的347例III期非小细胞肺癌患者。
- 患者接受根治性放化疗,计划剂量为50 Gy(大分割)或>60 Gy(常规分割)。
- 采用多因素frailty模型评估放疗计划方式对总生存的影响,并调整治疗开始时大体肿瘤体积、年龄、性别、同步化疗、肺部合并症、放疗剂量和肿瘤分级。
主要发现
- 患者以男性为主(n=269,78.4%),主要为腺癌(56.4%),平均年龄67.2岁。
- 适应性放疗并连续缩减照射体积对患者生存无显著不利影响(HR=1.21,95%CI 0.89-1.64)。
- 放疗计划中使用PET/CT融合趋向于更好的肿瘤学结局,但无显著关联(HR=0.8,95%CI 0.56-1.16)。
- 具有一致计划策略的中心表现优于无偏好计划方法的中心(0.62,95%CI 0.41-0.94)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Stage III non-small cell lung cancer (NSCLC) represents a highly heterogeneous disease and treatment burden. Advances in imaging modality show promising results for radiotherapy planning. In this multicentric study, we evaluated the impact of PET/CT-based radiotherapy planning on the prognosis of patients with stage III NSCLC. METHOD AND PATIENTS: A retrospective observational cohort study (ARO 2017-01/NCT03055715) was conducted by the young DEGRO trial group of the German Society for Radiation Oncology (DEGRO) with the primary objective to assess the effect of tumour volume change during chemoradiotherapy and the secondary objective to assess the effect of treatment planning on survival. Three hundred forty-seven patients with stage III NSCLC treated at 21 university centers between January 2010 and December 2013 were enrolled in this trial. Patients received primary curative chemoradiotherapy with an intended dose of 50 Gy (hypofractionated) or > 60 Gy (normofractionated). To assess the effect of radiotherapy planning modality on overall survival, we used multivariate frailty models. Models were adjusted for gross tumor volume at the initiation of therapy, age, sex, simultaneous chemotherapy, lung comorbidities, RT dose and tumor grade. By considering the random effect, we can account for heterogeneity in survival and considered covariates within the model in relation to the study side. RESULTS: Patients were predominantly male (n = 269, 78.4%) with mainly adenocarcinoma (56.4%) and an average of 67.2 years. Adaptation of radiotherapy with consecutive reduction of irradiation volume showed no significant disadvantage for patient survival (HR = 1.21, 95% CI 0.89-1.64). The use of PET/CT co-registration in radiation planning tended to result in better oncologic outcomes, although no significant association could be shown (HR = 0.8, 95% CI 0.56-1.16). Centers with a consistent planning strategy performed better than those without a preferred planning method (0.62, 95% CI 0.41-0.94). CONCLUSION: A consistent planning strategy has positive effects on overall survival. The use of PET/CT-based adaptive radiotherapy planning shows a similar survival prospect with the prospective of lower treatment volumes. In future research, toxicities need to be analysed in order to assess such reasoning.
引用
- Mäurer M, Käsmann L, Fleischmann DF, et al. PET/CT-based adaptive radiotherapy of locally advanced non-small cell lung cancer in multicenter yDEGRO ARO 2017-01 cohort study. Radiat Oncol. 2022. PMID: 35139856. doi:10.1186/s13014-022-01997-5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。